Board/Management Information • Oct 3, 2017
Board/Management Information
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information
RNS Number : 5454S
Mediclinic International plc
03 October 2017
Mediclinic International plc
(Incorporated in England and Wales)
Company Number 8338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
("Mediclinic" or "the Company")
APPOINTMENT OF DR FELICITY A. H. HARVEY CBE AS AN INDEPENDENT NON-EXECUTIVE DIRECTOR
3 October 2017
Mediclinic announces that Dr Felicity A. H. Harvey CBE is to join its Board as an Independent Non-Executive Director and an additional member of the Clinical Performance and Sustainability Committee with effect from 3 October 2017.
Dr Edwin Hertzog, Chairman of Mediclinic, commented:
"The Board is delighted to welcome Dr Harvey as a Non-Executive Director of the company and a member of the Clinical Performance and Sustainability Committee. Her thorough knowledge of the health sector as well as her broad general experience will be a valuable addition to the Board."
Dr Harvey is a visiting professor at the Institute of Global Health Innovation, Imperial College London; a non-executive director of Guy's and St Thomas' NHS Foundation Trust, London; a trustee of Royal Trinity Hospice, London; a member of the United Nations' Secretary General's Global Health Crises Task Force; and a member of the WHO Independent Oversight & Advisory Committee for Health Emergencies. Previously, she was Director-General of Public and International Health at the UK Department of Health; Director of the UK Prime Minister's Delivery Unit; Head of the Medicines, Pharmacy and Industry Group at the Department of Health; Director of Prison Health at Her Majesty's Prison Service; Head of Quality Management at NHS Executive; and Private Secretary to the Chief Medical Officer. Dr Harvey qualified in medicine in 1980, is an Honorary Fellow of the Royal College of Physicians and a Fellow of the Faculty of Public Health. She has an international MBA from Henley Management College, and gained further qualifications in clinical microbiology.
There are no disclosures required pursuant to paragraphs (1) to (6) of LR 9.6.13 R of the UK Listing Authority's Listing Rules in respect of this appointment. Dr Harvey's fees will amount to £66,600 per annum, in-line with current independent non-executive directors.
Following Dr Harvey's appointment to the Board, the Clinical Performance and Sustainability Committee will continue to be chaired by Dr Edwin Hertzog and its members will comprise Dr Felicity Harvey, Nandi Mandela, Danie Meintjes and Prof Dr Robert Leu.
Mediclinic is an international private healthcare group with operating platforms in Southern Africa (South Africa and Namibia), Switzerland and the United Arab Emirates. Its core purpose is to enhance the quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary healthcare services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a LSE listed and UK-based private healthcare group.
Mediclinic comprises 75 hospitals and 29 clinics. Mediclinic Southern Africa operates 49 hospitals and 2 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 000 inpatient beds in total; Hirslanden operates 17 private acute care facilities and 4 clinics in Switzerland with more than 1 700 inpatient beds; and Mediclinic Middle East operates 6 hospitals and 23 clinics with more than 700 inpatient beds in the United Arab Emirates.
During February 2016, the combination of the Company (previously named Al Noor Hospitals Group plc), with operations mainly in Abu Dhabi in the United Arab Emirates, and Mediclinic International Limited was completed. Mediclinic International Limited was a South African based international private healthcare group founded in 1983 and listed on the JSE, the South African stock exchange, since 1986, with operations in South Africa, Namibia, Switzerland and the United Arab Emirates (mainly in Dubai). The combination resulted in the renaming of the enlarged group to Mediclinic International plc.
Mediclinic has a primary listing on the Main Market of the LSE, with secondary listings on the JSE in South Africa and the NSX in Namibia.
For further information, please contact:
Victoria Dalby / Caroline Emmet
+44 (0)20 7954 9600
James Arnold, Head of Investor Relations
+44 (0)20 3786 8181
FTI Consulting
Brett Pollard/Debbie Scott (UK)
+44 (0)20 3727 1000
Frank Ford (South Africa)
+27 (0)21 487 9000
Registered address: 1st Floor, 40 Dukes Place, London, EC3A 7NH, United Kingdom
Website: www.mediclinic.com
Corporate broker: Morgan Stanley & Co International plc
JSE sponsor: RAND MERCHANT BANK (A division of FirstRand Bank Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAUGGCGUUPMUBW
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.